Gene therapy for blindness.

  title={Gene therapy for blindness.},
  author={Jos{\'e}-Alain Sahel and Botond M. Roska},
  journal={Annual review of neuroscience},
  • J. Sahel, B. Roska
  • Published 10 July 2013
  • Biology, Medicine
  • Annual review of neuroscience
Sight-restoring therapy for the visually impaired and blind is a major unmet medical need. Ocular gene therapy is a rational choice for restoring vision or preventing the loss of vision because most blinding diseases originate in cellular components of the eye, a compartment that is optimally suited for the delivery of genes, and many of these diseases have a genetic origin or genetic component. In recent years we have witnessed major advances in the field of ocular gene therapy, and proof-of… 

Figures from this paper

Restoring Vision to the Blind: Gene Therapy for Vision Loss: The Road Ahead

There are several technical and logistical issues that are seen as hurdles in the development path that are either specific to particular approaches/indications or shared among many.

Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances

The recent progress in attempts to restore visual function to the degenerate retina using optogenetic therapy is reviewed, with a focus on multiple pre-clinical models used in optogenetics strategies, which are discussed to discuss their strengths and limitations.

Let There Be Light: Gene and Cell Therapy for Blindness.

The present review outlines advances in therapies for retinal degenerative disease, focusing on the progress and challenges in the development and clinical translation of gene and cell therapies.

The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease

A comprehensive review of the approaches currently in development including a discussion of retinal neuroprotection, gene therapies (gene augmentation, gene editing, RNA modification, optogenetics), and regenerative stem or precursor cell-based therapies discusses the advantages and limitations for each approach.

Gene therapy of inherited retinal degenerations: prospects and challenges.

These strategies are summarized, including safe delivery of viral vectors to the outer retina, treatment of dominant IRDs as well as of IRDs caused by mutations in large genes, and selection of the appropriate IRDs and patients to maximize the efficacy of gene transfer.

Emerging therapies for inherited retinal degeneration

In individual patients, disease stage will determine whether the therapeutic strategy should comprise photoreceptor cell rescue to delay or arrest vision loss or retinal replacement for vision restoration.

Gene therapies for inherited retinal disorders

The next decade should result in an increasing number of preclinical studies progressing to human clinical trial, an exciting prospect for patients, those active in research and development and bystanders alike.

The primate model for understanding and restoring vision

The value of the NHP models in understanding human vision is explored and their contribution to the development of innovative therapeutic strategies to save and restore vision is reviewed.

Gene editing preserves visual function in a mouse model of retinal degeneration

A CRISPR/Cas9-based therapy is validated as a valuable new approach for the treatment of retinitis pigmentosa caused by autosomal recessive loss-of-function point mutations and preservation of light-evoked responses both in explanted retinas and in the visual cortex of treated animals.



Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy.

It is demonstrated in a transgenic mouse simulating human RHO-adRP that RNA interference-based suppression, together with gene replacement utilizing the endogenous mouse gene as the replacement, provides significant benefit as evaluated by electroretinography (ERG), which is mirrored histologically by preservation of photoreceptors.

Stem cells as a therapeutic tool for the blind: biology and future prospects

This work proves that residual retinal circuits can be reawakened after photoreceptor loss and defines a goal for stem-cell-based therapy to replace photoreceptors in blind patients.

Animal models of retinal disease.

AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness

The researchers report that the lack of immune response and the robust safety profile in this readministration gene therapy study may be due in part to the immune-privileged nature of the eye, and the low dose and very pure preparation of the AAV vector.

AAV-mediated gene supply for treatment of degenerative and neovascular retinal diseases.

Studies on AAV-mediated gene supply of neurotrophic/antiapoptotic factors to prevent retinal neurons degeneration, and anti-angiogenic molecules to inhibit retinal neovascularization are reviewed to represent a one-fit-all treatment for inherited and acquired blinding diseases.

Gene therapy rescues cone function in congenital achromatopsia.

It is demonstrated that rAAV-mediated gene replacement therapy with different forms of the human red cone opsin promoter led to the restoration of cone function and day vision in two canine models of CNGB3 achromatopsia, a neuronal channelopathy that is the most common form of achrom atopsia in man.

Gene therapy restores vision in a canine model of childhood blindness

The results indicate that visual function was restored in this large animal model of childhood blindness, and gene therapy directed at photoreceptors and RPE in a large-animal model of human disease has not been reported.

Optogenetic therapy for retinitis pigmentosa

The potential and limitations of optogenetic engineering for the treatment of RP are discussed and artificial photoreceptors constructed by gene delivery of light-activated channels or pumps to surviving cell types in the remaining retinal circuit are discussed.

The human visual cortex responds to gene therapy-mediated recovery of retinal function.

Functional MRI data suggest that despite severe and long-term visual impairment, treated LCA2 patients have intact and responsive visual pathways, and suggest that gene therapy resulted in not only sustained and improved visual ability, but also enhanced contrast sensitivity.

Effect of gene therapy on visual function in Leber's congenital amaurosis.

Three young adult patients with early-onset, severe retinal dystrophy were administered subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human R PE65 promoter.